What is the Novavax COVID-19 Vaccine?

Novavax COVID-19 Vaccine, Adjuvanted contains the Omicron XBB.1.5 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells.

It is authorized for emergency use in people age 12 years or older as a two-dose primary series for previously unvaccinated individuals (whether or not they are immunocompromised), with the doses given at least 3 to 8 weeks apart. Individuals who have had one or more doses of any previous authorized or approved COVID-19 vaccine formulation are recommended to receive only one dose of the current formulation. An additional dose of Novavax or any other COVID-19 vaccine is recommended for adults age 65 years or older at least 4 months after their first dose of the 2023-2024 Formula COVID-19 vaccine. Individuals with moderate or severe immunocompromise may receive additional doses as determined by their healthcare team, based on their specific circumstances.